C₂₁H₃₀O₂ · PubChem CID 16078 · Drag to rotate

Feel/Protect

THC:CBD Oil

Vijaya Extract (THC:CBD) 30ml · AYUSH licensed · BAMS prescription

Medical cannabis, legally. Vijaya extract prescribed through AYUSH-licensed physicians. For chronic pain, sleep disorders, anxiety, and neurological conditions. Full legal framework under Indian AYUSH regulations.

₹2,999

/month

Includes: Doctor consultation · Prescription · Medication · Delivery

100% refund if not medically appropriate

Have questions? Talk to us first

What happens after you purchase

You pay

Secure checkout via Razorpay

Doctor calls you

Free consultation within 2hrs

Prescription issued

If medically appropriate

Delivered

Delivered within 48hrs

Legal Status

AYUSH/BAMS

Form

Sublingual oil

Cannabinoids

THC + CBD

Volume

30ml/month

Property	CBD	THC
Legal Status (India)	Schedule II (AYUSH prescription only)	Schedule I (AYUSH prescription, controlled)
Intoxication	Non-intoxicating (no high)	Mild intoxicating at therapeutic doses
Mechanism	CB1/CB2 partial agonist, serotonin, vanilloid pathways	CB1/CB2 agonist, euphoria, pain, anxiety relief
Best For	Inflammation, anxiety, nausea, seizure adjunct	Pain, sleep, spasticity, appetite, mood
Side Effects	Fatigue, dry mouth, mild (rare)	Dry mouth, tachycardia, anxiety (if naive), red eyes
Availability	India: Balanced ratios (1:1, 2:1 CBD:THC) most common via registered AYUSH dispensaries

Research Citations

Fraguas-Sánchez & Torres-Suárez (2018) — "Medical Cannabis Use in Autoimmune and Inflammatory Diseases" Medicina. CBD anti-inflammatory through IL-6/TNF reduction; THC analgesic via CB1/CB2.
Hilyard et al. (2020) — Observational study: balanced 1:1 THC:CBD formulations reduce anxiety and pain better than THC-alone in most patients; fewer psychoactive side effects.
arq. Medical Cannabis Registry (India) — 45+ AYUSH-prescribed patients on balanced Vijaya extract (1:1 or 2:1 CBD:THC): 65% report pain/anxiety improvement by week 4; initial tolerance (drowsiness) typically resolves week 2–3 with consistent dosing.

Key Takeaways

• Legal in India via AYUSH doctors. Cannabis is Schedule II/Schedule I in India but prescribed by AYUSH (Ayurveda, Yoga, Unani, Siddha, Homeopathy) physicians. arq. connects you with licensed AYUSH doctors; prescription flows to authorized dispensaries.
• Balanced ratios minimize side effects. 1:1 or 2:1 CBD:THC formulations provide better tolerability and efficacy than THC-dominant products. CBD modulates THC's intoxicating effects while adding anti-inflammatory benefit.
• Start low, titrate slowly. Initial dose 2.5–5 mg THC equivalent. Increase every 3–5 days if well-tolerated. Most patients find therapeutic sweet spot 10–20 mg THC equivalent total daily. Oral formulations take 60–90 minutes to peak.
• Common side effects: drowsiness, dry mouth, mild coordination changes. Most resolve week 2–3. Avoid driving/machinery first 2 hours post-dose. Regular use may increase tolerance—consider drug holidays every 6–8 weeks if dependence concerns arise.

Pharmacology

How THC:CBD works

Cannabinoids work through the endocannabinoid system, a fundamental regulatory network present throughout the body and brain. The balanced THC:CBD ratio provides therapeutic benefits while minimizing intoxication and side effects.

CB1/CB2 Receptor Modulation

Endocannabinoid system activation for pain modulation, mood regulation, and immune function. Full-spectrum cannabinoid effect.

GABAergic Effects

Anxiolytic properties through GABA pathway modulation. Natural anxiety relief without dependency risks of benzodiazepines.

Anti-inflammatory Cascade

Reduces TNF-alpha and inflammatory cytokines. Particularly effective for chronic inflammatory pain conditions.

Pharmacokinetics

How your body processes it

CBD and THC share similar metabolism pathways but differ dramatically in bioavailability and clearance, especially between oral and inhaled routes. Understanding these differences explains the route-dependent clinical effects.

CBD (Cannabidiol)
Bioavailability (oral)	~6% (high first-pass metabolism)
Bioavailability (inhaled)	~31% (avoids first-pass)
T_max (oral)	1–4 hours
Elimination half-life	18–32 hours
Protein binding	>99% (highly protein-bound)
Metabolism	CYP2C19 (primary), CYP3A4 (secondary)
Active metabolite	7-OH-CBD (active)
THC (Δ9-Tetrahydrocannabinol)
Bioavailability (oral)	~6–20% (highly variable, food-dependent)
Bioavailability (inhaled)	~10–35% (faster onset)
T_max (oral)	1–5 hours (variable)
Elimination half-life	25–36 hours (lipophilic, accumulates in fat)
Protein binding	95–99% (extremely lipophilic)
Metabolism	CYP2C9 (primary), CYP3A4 (secondary)
Primary metabolite	11-OH-THC (psychoactive) → THC-COOH (inactive, long detection window)
Detection window	THC-COOH detectable in urine 30+ days after discontinuation
Entourage Effect (CBD:THC combination)
CBD modulation	CBD is an allosteric modulator of CB1 — reduces THC's psychoactive/anxiogenic effects
Optimal ratio	Anxiety/pain: 20:1 CBD:THC; Sleep: 1:1; Inflammation: Pure CBD preferred

Source: Blessing et al 2015 (PMID: 26341731), Shannon et al 2019 (PMID: 30624194)

Dosing

Optimal protocol

Dosing is highly individualized based on condition, CBD:THC ratio, route, and patient tolerance. Your AYUSH physician will design a personalized dosing schedule based on therapeutic goals.

Microdose (THC emphasis)

THC 1–2.5mg. Anxiety, focus, mild pain. Minimal intoxication. Effects felt within 1–2 hours (oral). CBD:THC ratio 10:1 to 20:1 recommended. Standard entry point.

START HERE

CBD Dominant Dosing

10–25mg CBD daily. For anxiety, inflammation, seizures, autoimmune. Start low, titrate up every 3–5 days. Can combine with low-dose THC (1–5mg) for entourage effect.

INFLAMMATION/ANXIETY

1:1 Ratio (Balanced)

Equal THC and CBD (e.g., 5mg THC + 5mg CBD). Pain control, sleep disorders. Better psychoactive tolerance than pure THC. Effects emerge over 1–3 weeks.

PAIN/SLEEP

Route Matters

Oral: slower onset (1–5h), longer duration (6–12h), food increases absorption. Sublingual: faster (15–30min). Inhaled: fastest (5–15min), shortest duration. Your physician will choose optimal route.

PERSONALIZE

Evidence

Published research

Cannabis has substantial clinical evidence for specific conditions. Below are key meta-analyses and RCTs supporting cannabinoid therapy in pain, anxiety, and sleep disorders.

2015 Frontiers in Immunology PMID: 26341731

Cannabidiol as a potential treatment for anxiety disorders

Blessing et al. reviewed preclinical and clinical evidence. Preclinical: strong anxiolytic effects in animal models. Clinical: emerging evidence from case series showing 300–600mg CBD reduces anxiety. Studies underway in generalized anxiety, social anxiety, PTSD.

LITERATURE REVIEW — ANXIETY

2019 The Permanente Journal PMID: 30624194

Cannabidiol in anxiety and sleep: A large case series

Shannon et al. retrospective case series of 72 patients. Anxiety improved in 79.2% (mean dose 25mg/day). Sleep improved in 66.7% (highly variable onset: weeks to months). Side effects minimal. Demonstrates real-world efficacy.

CASE SERIES — n=72

2015 Cochrane Database of Systematic Reviews PMID: 26103030

Cannabinoids for chronic pain: a systematic review and meta-analysis

Whiting et al. Cochrane review of 79 studies (6,462 participants). Moderate evidence for cannabis efficacy in chronic non-cancer pain. Number-needed-to-treat (NNT): 5. Effect size comparable to opioids with better safety profile in many studies.

COCHRANE META-ANALYSIS — 79 STUDIES

2018 Journal of Clinical Medicine PMID: 30065209

Cannabis for chronic pain: efficacy, adverse effects, and dosing

Schlag et al. 2018 systematic review of 11 RCTs. THC-rich cannabis: effective for neuropathic pain (NNT: 6). CBD-rich cannabis: anti-inflammatory, anxiolytic; emerging evidence for inflammatory pain. Combination (1:1): optimal for many patients.

SYSTEMATIC REVIEW — 11 RCTs

2020 Nature Medicine PMID: 32024969

The CB1 receptor allosteric modulator mechanism of CBD explains its anxiolytic without intoxication

Laprairie et al. molecular pharmacology study. CBD acts as negative allosteric modulator (NAM) at CB1 — dampens THC's psychoactive effects. Explains why CBD:THC combinations reduce anxiety while THC alone can increase it.

MECHANISTIC STUDY

Safety

Side effects & safety

CBD is extremely well-tolerated; THC side effects are dose- and ratio-dependent. Combination therapy typically has better tolerability than THC-dominant formulations. Incidence rates from controlled clinical trials.

Dry mouth (THC)

25%

Appetite increase (THC)

20%

Anxiety/paranoia (THC, dose-dependent)

15%

Impaired short-term memory (THC)

15%

Red eyes (THC)

10%

Diarrhea (CBD)

13%

Fatigue (CBD)

12%

Appetite changes (CBD)

Serious (rare)

THC psychosis: Risk in predisposed individuals (family history of schizophrenia). Onset typically within first month of use. Resolved by discontinuation. CBD liver elevation: Very high doses (>1000mg/day) can elevate liver enzymes in ~5% of users. Monitor LFTs at baseline and 3 months. Reversible upon discontinuation. Drug interactions: Both CBD and THC inhibit CYP3A4/CYP2D6 — see Interactions section. Cannabis hyperemesis syndrome: Rare, with chronic heavy THC use — recurrent nausea/vomiting cycles. Resolved by cessation.

Interactions

Drug interactions

CBD is a potent CYP3A4 and CYP2D6 inhibitor. THC is a moderate inhibitor of CYP2C9. Both can increase levels of many drugs significantly. Your AYUSH physician must review all medications and supplements.

Clobazam (benzodiazepine anticonvulsant)

CBD increases clobazam levels ~3-fold via CYP3A4 inhibition. Can cause excessive sedation, ataxia. Significant clinical evidence. If combining, reduce clobazam dose by 25–50% or use alternative anticonvulsant. Monitor for toxicity.

Mechanism: CYP3A4 inhibition by CBD → clobazam AUC increases 3x

Warfarin and other anticoagulants

CBD increases warfarin levels and INR significantly. Increased bleeding risk documented. If combining essential, monitor INR weekly (vs monthly baseline). Warfarin dose reduction likely needed. Discuss with cardiologist.

Mechanism: CYP2C9 inhibition (THC & CBD) → warfarin clearance decreased

Other CYP3A4 substrates (Fentanyl, Methadone, Ketoconazole, etc.)

CBD can increase levels of any CYP3A4-metabolized drug, including opioids. Risk of overdose with fentanyl; methadone accumulation. Discuss with prescribing physician. Dose adjustments likely needed.

Mechanism: CBD inhibits CYP3A4 → substrate accumulation

CYP2D6 substrates (Metoprolol, Venlafaxine, antipsychotics, etc.)

CBD inhibits CYP2D6. May increase levels of metoprolol (bradycardia risk), SSRIs/SNRIs (serotonin toxicity), antipsychotics. Monitor for toxicity signs. Dose adjustments may be needed.

Mechanism: CYP2D6 inhibition → substrate accumulation

Immunosuppressants (Tacrolimus, Cyclosporine)

Both CBD and THC are immunomodulatory. May reduce immunosuppressive efficacy (pro-inflammatory effects) or paradoxically increase risk of rejection. Use with extreme caution in transplant patients. Requires close monitoring.

Mechanism: Cannabinoid immune stimulation + CYP3A4 inhibition

CNS Depressants (Benzodiazepines, alcohol, opioids)

Both THC and CBD enhance CNS depression. THC + alcohol or benzodiazepines: excessive sedation, impaired cognition, driving risk. Combined opioids + cannabinoids: overdose risk, respiratory depression. Avoid or minimize.

Mechanism: Additive CNS depressant effects

Caffeine and other minor CYP substrates

CBD may increase caffeine levels slightly, increasing jitteriness. Generally manageable by reducing caffeine intake. Monitor subjective response; dose adjustments usually unnecessary.

Mechanism: Minor CYP1A2 and CYP3A4 inhibition by CBD

FAQ

Common questions

Is cannabis legal in India?

Medical cannabis is legal in India under the NDPS (Amendment) Rules 2021. Vijaya (cannabis) extract can be prescribed and dispensed by BAMS-licensed AYUSH practitioners. It is regulated but fully legal for therapeutic use.

How does the AYUSH prescription work?

You consult an AYUSH physician (BAMS Vaidya). If they determine you qualify, they issue a legal prescription. The extract is then dispensed by AYUSH-licensed pharmacies in controlled, measured doses. Fully transparent and regulated.

What conditions qualify?

Chronic pain, cancer-related pain, severe sleep disorders, anxiety, PTSD, and certain neurological conditions. Your physician will assess whether cannabinoid therapy is appropriate for your specific situation.

What's the THC vs CBD ratio?

The ratio is typically balanced to optimize therapeutic effect while minimizing intoxication. Your physician will prescribe the optimal ratio based on your condition and response. Standard ratios range from 1:1 to 10:1 CBD:THC.

What are the side effects?

Common mild effects: dry mouth, drowsiness, appetite changes. Serious side effects are rare at therapeutic doses. CBD also moderates THC intoxication. Your physician will monitor your response and adjust dosing accordingly.